Today's Small-Cap Winners and Losers
II-VI (IIVI), a maker of optical components, rose sharply a day after its earnings beat Wall Street's third-quarter expectations. The company made $7.5 million, or 25 cents a share, up from $5.8 million, or 19 cents a share, a year ago. Revenue for the quarter increased 11% to $59.4 million. Two analysts were looking for earnings of 21 cents.
For the fourth quarter, II-VI forecast revenue of $61 million to $63 million and earnings of 24 cents to 28 cents a share. Full-year revenue should be $229 million to $231 million with earnings of 89 cents to 93 cents, II-VI said. Shares of II-VI were up $2.84, or 16.4%, to $20.18.
GoAmerica (GOAM), a provider of communications services for people who are deaf, hard-of-hearing or have speech disabilities, rocketed nearly 46% higher after the company's i711.com was chosen as the exclusive IP-based relay service for Nordia's California Relay Services contract.
Nordia, one of three state contract holders that provide relay services to California, previously offered its own IP relay service. Shares of GoAmerica were up $1.54 to $4.90.North American Scientific (NASI) saw its shares jump following news that it received clearance from the Food and Drug Administration to market a brachytherapy product for breast cancer. Brachytherapy, or internal radiation therapy, uses radioactive sources or seeds to treat tumors. North American's stock was up 44 cents, or 20%, to $2.63. Shares of Discovery Laboratories (DSCO) were getting hammered a day after the company said the U.S. regulatory approval process for Surfaxin, a product for preventing respiratory distress syndrome in premature infants, could be significantly delayed. The reason is that data on Surfaxin's stability weren't sufficient, and new test batches will probably have to be produced. Because of the delay, Discovery is analyzing all aspects of its business with an immediate goal of conserving cash. Establishing "a commercial infrastructure" is no longer in its near-term plans, the company said. Shares of Discovery were sinking $2.36, or 50.3%, to $2.33.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV